On September 2, EVEREST MED rose 6.56% in regular trading, trading at 34.58 HKD/share, with turnover of 84.25 million HKD. The stock rebounded sharply after declining 6.29% on August 31, when prior profit-taking weighed on shares following a cumulative rally of over 55% since August 20.
The earlier surge was catalyzed by Moderna and Merck's announcement that their mRNA personalized cancer vaccine achieved positive Phase III clinical results — the first such success for the mRNA oncology approach. EVEREST MED, which holds an end-to-end mRNA platform including AI-driven neoantigen prediction algorithms and a self-built GMP facility, was identified as a key domestic beneficiary. The company's EVM14 pipeline is the only mRNA tumor vaccine from a domestically listed company to receive FDA IND approval.
Fundamentally, the company reported H1 revenue of RMB 1.148 billion, up 157% year-over-year, achieving near-breakeven with adjusted net profit of RMB 97 million. Core product Nefecon generated RMB 889 million in sales, up 94%. Multiple brokerages maintain Buy ratings, with a consensus target of 55.36 HKD.
Within the Biotechnology sector, CANSINOBIO rose 6.92%, AKESO rose 1.93%, and BEONE MEDICINES rose 1.59%, signaling a broader sector recovery.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments